TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 33.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 123,401 shares of the biopharmaceutical company's stock after acquiring an additional 31,124 shares during the period. Los Angeles Capital Management LLC owned about 0.08% of TG Therapeutics worth $2,886,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 485 shares during the last quarter. Quarry LP lifted its holdings in TG Therapeutics by 9.1% in the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 503 shares during the period. Private Advisor Group LLC grew its position in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after buying an additional 542 shares during the last quarter. Blue Trust Inc. lifted its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 849 shares during the period. Finally, Swiss National Bank lifted its position in shares of TG Therapeutics by 0.5% in the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company's stock worth $4,321,000 after purchasing an additional 1,500 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $3.99 during trading hours on Wednesday, reaching $34.90. The stock had a trading volume of 9,882,763 shares, compared to its average volume of 3,690,263. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $5.43 billion, a PE ratio of -349.00 and a beta of 2.19. TG Therapeutics, Inc. has a 52 week low of $10.42 and a 52 week high of $36.24. The company has a 50 day moving average price of $24.41 and a two-hundred day moving average price of $20.89.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million during the quarter, compared to analysts' expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's quarterly revenue was down 49.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 earnings per share. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.50% of the company's stock.

Wall Street Analyst Weigh In

TGTX has been the subject of several research reports. HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. B. Riley upped their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and an average target price of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.